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A B S T R A C T
Background
Miscarriage is a common complication encountered during pregnancy. It is defined as spontaneous pregnancy loss before 20 weeks’
gestation. Progesterone’s physiological role is to prepare the uterus for the implantation of the embryo, enhance uterine quiescence and
suppress uterine contractions, hence, it may play a role in preventing rejection of the embryo. Inadequate secretion of progesterone
in early pregnancy has been linked to the aetiology of miscarriage and progesterone supplementation has been used as a treatment
for threatened miscarriage to prevent spontaneous pregnancy loss. This update of the Cochrane Review first published in 2007, and
previously updated in 2011, investigates the evidence base for this practice.
Objectives
To determine the efficacy and the safety of progestogens in the treatment of threatened miscarriage.
Search methods
We searchedCochrane Pregnancy andChildbirth’s Trials Register, ClinicalTrials.gov and theWHOInternational Clinical Trials Registry
Platform (ICTRP) (8 August 2017) and reference lists of retrieved trials.
Selection criteria
Randomised, quasi-randomised or cluster-randomised controlled trials, that compared progestogen with placebo, no treatment or any
other treatment for the treatment of threatened miscarriage in women carrying singleton pregnancy.
Data collection and analysis
At least two review authors assessed the trials for inclusion in the review, assessed trial quality and extracted the data and graded the
body of evidence.
Main results
We included seven trials (involving 696 participants) in this update of the review. The included trials were conducted in different
countries, covering the full spectrum of the World Bank’s economic classification, which enhances the applicability of evidence drawn
from this review. Two trials were conducted in Germany and Italy which are high-income countries, while four trials were conducted in
upper-middle income countries; two in Iran, one in Malaysia and the fourth in Turkey, and the seventh trial was conducted in Jordan,
which is a lower-middle income country. In six trials all the participants met the inclusion criteria and in the seventh study, we included
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in the meta-analysis only the subgroup of participants who met the inclusion criteria. We assessed the body of evidence for the main
outcomes using the GRADE tool and the quality of the evidence ranged from very low to moderate. Downgrading of evidence was
based on the high risk of bias in six of the seven included trials and a small number of events and wide confidence intervals for some
outcomes.
Treatment of miscarriage with progestogens compared to placebo or no treatment probably reduces the risk of miscarriage; (risk ratio
(RR) 0.64, 95%confidence interval (CI) 0.47 to 0.87; 7 trials; 696women;moderate-quality evidence). Treatmentwith oral progestogen
compared to no treatment also probably reduces the miscarriage rate (RR 0.57, 95% CI 0.38 to 0.85; 3 trials; 408 women; moderate-
quality evidence). However treatment with vaginal progesterone compared to placebo, probably has little or no effect in reducing the
miscarriage rate (RR 0.75, 95% CI 0.47 to 1.21; 4 trials; 288 women; moderate-quality evidence). The subgroup interaction test
indicated no difference according to route of administration between the oral and vaginal subgroups of progesterone.
Treatment of miscarriage with the use of progestogens compared to placebo or no treatment may have little or no effect in reducing
the rate of preterm birth (RR 0.86, 95% CI 0.52 to 1.44; 5 trials; 588 women; low-quality evidence).
We are uncertain if treatment of threatened miscarriage with progestogens compared to placebo or no treatment has any effect on the
rate of congenital abnormalities because the quality of the evidence is very low (RR 0.70, 95% CI 0.10 to 4.82; 2 trials; 337 infants;
very-low quality evidence).
Authors’ conclusions
The results of this Cochrane Review suggest that progestogens are probably effective in the treatment of threatened miscarriage but
may have little or no effect in the rate of preterm birth. The evidence on congenital abnormalities is uncertain, because the quality of
the evidence for this outcome was based on only two small trials with very few events and was found to be of very low quality.
P L A I N L A N G U A G E S U M M A R Y
Progestogen for treating threatened miscarriage
What is the issue?
Spontaneous miscarriage occurs in about 15% to 20% of pregnancies. Threatened miscarriage occurs when a mother might be losing
her baby at less than 20 weeks’ gestation. The symptoms of threatened miscarriage are vaginal bleeding, with or without abdominal
pain, while the cervix of the womb is closed and the baby inside the womb is alive. Progesterone is a hormone that is known to prepare
the uterus for implantation of the fertilized egg and suppress uterine contractions until term. Medications that mimic the action of
progesterone are known as progestogens. Treatment with progestogens may be effective in reducing the rate of miscarriage in women
who have threatened miscarriage. This Cochrane Review examines whether progestogens could reduce miscarriage for women with
threatened miscarriage, and also addresses the safety of these medications for mother and baby.
Why is this important?
We were interested to investigate if progestogens are effective and safe in the treatment of threatened miscarriage, which may increase
the women’s chances of having a successful pregnancy and a live birth.
What evidence did we find?
In this review of the literature, up to August 2017, we identified seven randomised trials involving 696 women that compared the use
of progestogens in the treatment of threatened miscarriage with either placebo or no treatment. We found that the use of a progestogen
probably reduces the rate of spontaneous miscarriage and this was supported by moderate-quality evidence. Five trials, involving 588
women, reported on the effectiveness of progestogens given for threatened miscarriage in reducing the rate of preterm delivery and
showed little or no effect, with low-quality evidence. Two trials, involving 337 women, reported on the effect of treatment with
progestogens given for threatened miscarriage on the rate of occurrence of congenital abnormalities in the newborns. The evidence on
congenital abnormalities is uncertain, because the quality of the evidence for this outcome was based on only two small trials with very
few events and was found to be of very low quality.
What does this mean?
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The evidence suggests that progesterone probably reduces the rate of spontaneous miscarriage but may make little or no difference to
the number of preterm deliveries. The evidence for congenital abnormalities is uncertain because the quality of the evidence for this
outcome was based on only two small trials with very few events and was found to be of very low quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Progesterone compared to placebo or no treatment for treating threatened miscarriage
Patient or population: women with threatened miscarriage
Setting: two in high-income countries (Germany and Italy), four in upper-m iddle income countries (two in Iran, one in Malaysia and one in Turkey) and one in lower-income
country (Jordan). All in hospitals (university or women’s) or medical centres
Intervention: progesterone
Comparison: placebo or no treatment
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo or no
treatment
Risk with progesterone
Miscarriage Study populat ion RR 0.64
(0.47 to 0.87)
696
(7 RCTs)
⊕⊕⊕©
Moderate1
242 per 1000 138 per 1000
(102 to 189)
Preterm birth Study populat ion RR 0.86
(0.52 to 1.44)
588
(5 RCTs)
⊕⊕©©
Low1,2
91 per 1000 84 per 1000
(49 to 142)
Congent ial abnormali-
t ies
Study populat ion RR 0.70
(0.10 to 4.82)
337
(2 RCTs)
⊕©©©
Very low1,2,3
13 per 1000 9 per 1000
(1 to 62)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io
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GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Random sequence generat ion and/ or allocat ion concealment had a high or unclear risk of bias in the majority of the trials
(methodological quality of trials) (-1).
2Wide conf idence interval crossing the no ef fect line (imprecision) (-1).
3A small number of events (-1).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
“Miscarriage is pregnancy loss before 20 weeks’ gestation based
on the first day of the last menstrual period or, if gestation age is
unknown, it is the loss of an embryo or a fetus of less than 400 g”
(Zegers-Hochschild 2009). Threatened miscarriage is manifested
by vaginal bleeding, with or without abdominal pain, while the
cervix is closed and the fetus is viable and inside the uterine cavity (
Cunningham 2001a).Once the cervix begins to dilate,miscarriage
and pregnancy loss are inevitable.When the fetus is non-viable and
the cervix is closed, this is known as missed miscarriage or missed
abortion (Cunningham 2001a). The presence of a short cervix
or funnelling of the internal cervical os in the gestation period
between 16 and 24 weeks has been found to indicate increased
risk or threat to miscarriage (Owen 2004; Rust 2005).
Miscarriage is a common complication of pregnancy occurring in
15% to 20% of all clinically recognised pregnancies (Blohm 2008;
Cohain 2017). As many as 50% of the miscarried fetuses and
embryos have normal chromosomes (Suzumori 2010; Vorsanova
2005). In many cases, the cause of miscarriage cannot be iden-
tified, however, among the recognised risk factors of miscarriage
are maternal age over 34 years and paternal age over 40 years (De
La Rochebrochard 2002), previous history of two or more mis-
carriages (Sugiura-Ogasawara 2009), and maternal autoimmune
factors such as phospholipids antibodies (Check 2011). In addi-
tion, many modifiable risk factors were recognised including ma-
ternal obesity (Hahn 2014), maternal infection such as genital
herpes simplex, HIV-1 and vaginal colonisation of group B strep-
tococci (Nigro 2011; Rocchetti 2011; Temmerman 1992). Mater-
nal endocrine abnormalities such as uncontrolled diabetes melli-
tus (Galindo 2006), polycystic ovary syndrome (Arredondo 2006)
and insufficient production of progesterone are other known risk
factors. Progesterone insufficiency is due to corpus luteum (CL)
deficiency, which is a group of cells in the ovary that are formed
after the release of the ovum (Cunningham 2001b). The main
function of the CL is to produce sufficient progesterone to prepare
and support the lining of the uterus and facilitate implantation
of the ovum (Cunningham 2001b). It is suggested that proges-
terone deficiency in early pregnancy may be an aetiological factor
for miscarriage, hence, treatment with progesterone may prevent
miscarriage. However the evidence support for the effectiveness
and safety of such treatment is uncertain based on the results of
recently published trials (Coomarasamy 2015; Saccone 2017).
Description of the intervention
Progestogens are a group of hormones that bind to the proges-
terone receptors; they include both the natural female sex hormone
progesterone and the synthetic forms. Medications that mimic the
action of progesterone are known as progestational agents. Proges-
terone and progestational agents are known as progestogens. Pro-
gesterone is secreted during early pregnancy from the ovary by CL
(Cunningham 2001b). It is an essential hormone for the establish-
ment and maintenance of pregnancy. Progestogens can be given
to women with threatened miscarriage orally, as intramuscular in-
jection or in the form of vaginal suppositories. Due to the wide
range of doses, preparations and types of progestogens used for the
treatment of threatened miscarriage (Carp 2012; Mirza 2016), it
is uncertain what is the best type, dose and route of administration
for the treatment of threatened miscarriage.
How the intervention might work
Progesterone induces secretory changes in the lining of the uterus,
which are important for implantation of the fertilised ovum (Jin
2006). In addition, it modulates the immune response of the
mother to prevent rejection of the embryo through a protein
called progesterone induced blocking factor (PIBF), which is pro-
duced by the lymphocytes (white blood cells) of the pregnant
woman (Szekeres-Bartho 2010), and it enhances uterine quies-
cence and suppresses uterine contractions (Szekeres-Bartho 2008;
Szekeres-Bartho 2009). Low progesterone levels have been linked
to increased risk of first trimester miscarriage (Osmana ao lu
2010).
Owing to the documented physiological role of progesterone in
maintaining pregnancy, it has been used to treat women with
threatened miscarriage and presumed progesterone deficiency
to improve expectations for continuity of pregnancy (Palagiano
2004). The therapeutic value of progesterone in preventing or
treating threatened miscarriage has not been established (Kalinka
2005), although more recent evidence suggests that it may be ef-
fective in preventing miscarriage in women with a history of re-
current miscarriage of unclear etiology (Haas 2018). This might
be due to the poor designs of the trials done to evaluate its ef-
fectiveness (Kalinka 2005), and the inclusion of women in these
trials with different aetiologies for threatened miscarriage.
Why it is important to do this review
Miscarriage is associated with considerable physical and psycho-
logical morbidity. Women who had threatened miscarriage were
found to have increased rate of antepartum haemorrhage, pre-
labour rupture of the membranes, preterm delivery, and intrauter-
ine growth restriction when compared with women who did not
have threatened miscarriage (Saraswat 2010). The emotional re-
sponse tomiscarriage canbe profound; it includes depression, sleep
disturbance, anger, and marital disturbances (Marcinko 2011).
The introduction of ultrasound scans in themanagement of bleed-
ing in early pregnancy has improved the diagnosis by rapid con-
firmation of viability and has improved the management by in-
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troducing prognostic factors such as fetal bradycardia and discrep-
ancy between gestational age and crown-to-rump length (Dede
2010; Makrydimas 2003). This has rationalised the management
of threatenedmiscarriage, as attempts to maintain a pregnancy are
likely to be effective only if the fetus is viable and has no chromo-
somal abnormalities (Lede 2005).
The importance of progesterone on themaintenance of pregnancy
was demonstrated by the successful use of progesterone antago-
nists, such as mifepristone (RU 486) in the elective induction of
abortion (Dabash 2015). In a recently published systematic review
vaginally administered progesterone was more effective in the pre-
vention of preterm birth compared to the injectable progesterone
(Oler 2017). This raised the question about the importance of
the route of administration and the type of progestogen used to
prevent preterm labour (Di Renzo 2005). These same questions
might apply to the use of progestogens in the treatment of threat-
ened miscarriage.
In earlier reports progestogen therapy has been linked to the devel-
opment of hypospadias (deformity of the penis) in the male fetus
(Silver 1999); however, recent reports did not show an increase in
rate of hypospadias in infants of mothers who received progesto-
gens in early pregnancy (Källén 2010).
The aim of this review is to study all the available data on the
effectiveness of administration of progestogens for the treatment
of threatened miscarriage.
O B J E C T I V E S
To determine the efficacy and the safety of progestogens in the
treatment of threatened miscarriage.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised, quasi-randomised or cluster-ran-
domised controlled trials, that assessed the effectiveness and safety
of progestogens in the treatment of threatened miscarriage com-
pared to placebo, no treatment or other intervention, if viability of
the embryo or the fetus was confirmed before the commencement
of treatment.
Types of participants
We included pregnant women, with threatened miscarriage at or
less than 23 weeks, with singleton embryo or fetus, and who had
a confirmed viable pregnancy. Fetal viability was to ensure that
we excluded from this review trials that included women with
bleeding in early pregnancy due to missed miscarriage. We have
placed no restriction on the age of the woman or past obstetric
history.
Types of interventions
We included any type of progestogens, natural or synthetic, used
in the treatment of threatened miscarriage regardless of the dose,
duration or route of administration compared with placebo, no
treatment or other intervention.
Types of outcome measures
Primary outcomes
1. Miscarriage
Secondary outcomes
Mother
1. Pain relief (as defined by the study authors)
2. Thromboembolism
3. Preterm birth
4. Depression (as defined by the study authors)
5. Any other adverse outcomes that were reported (pregnancy-
induced hypertension; antepartum haemorrhage)
Child
1. Preterm birth
2. Stillbirth
3. Neonatal death
4. Congenital abnormalities, including genital malformations
5. Any other adverse neonatal outcomes that were reported
(intrauterine growth restriction; respiratory distress syndrome)
6. Low birthweight (not prespecified)
7. Birthweight (not prespecified)
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
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Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (8 August 2017)
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Two people screen the search results and review the full text of
all relevant trial reports identified through the searching activities
described above. Based on the intervention described, each trial re-
port is assigned a number that corresponds to a specific Pregnancy
and Childbirth review topic (or topics), and is then added to the
Register. The Information Specialist searches the Register for each
review using this topic number rather than keywords. This results
in a more specific search set that has been fully accounted for in
the relevant review sections (Included studies; Excluded studies;
Studies awaiting classification; Ongoing studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform ( ICTRP) for unpub-
lished, planned and ongoing trial reports (8 August 2017) using
the search terms given in Appendix 1.
Searching other resources
We scanned bibliographies of identified papers.
We did not apply any language restrictions.
Data collection and analysis
We have outlined the methods of data collection and analysis that
we used to assessGerhard 1987 and Palagiano 2004 in the previous
version of this review, Wahabi 2011.
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Three review authors independently assessed for inclusion all the
potential trials we identified as a result of the search strategy. We
resolved any disagreement through discussion.
Data extraction and management
Formethods used in the previous version of this review, seeWahabi
2011.
For this update, we used the following methods for assessing the
29 reports that the Information Specialist identified as a result of
the updated search.
Assessment of risk of bias in included studies
The four review authors independently assessed risk of bias for
each study using the criteria outlined in theCochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011b). We resolved
any disagreement by discussion.
(1) Random sequence generation (checking for possible
selection bias)
We described the method used to generate the allocation sequence
in sufficient detail to allow an assessment of whether it should
produce comparable groups.
For each included study we assessed the method as being at:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
For each included study we described the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as being at:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
For each included study we described the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that trials were
at low risk of bias if they were blinded, or if we judged that the
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lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as being at:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
For each included study we described the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as being
at:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
For each included study, and for each outcome or class of out-
comes, we described the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to out-
comes. Where sufficient information was reported, or could be
supplied by the trial authors, we planned to re-include missing
data in the analyses that we undertook.
We assessed methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
We excluded trials where more than 20% of participants were lost
to follow-up.
(5) Selective reporting (checking for reporting bias)
For each included study we described how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as being at:
• low risk of bias (where it was clear that all of the study’s
prespecified outcomes and all expected outcomes of interest to
the review have been reported);
• high risk of bias (where not all the study’s prespecified
outcomes were reported; one or more reported primary
outcomes were not prespecified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
For each included study we described any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether trials were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011b). With
reference to (1) to (6) above, we planned to assess the likely mag-
nitude and direction of the bias and whether we considered it was
likely to have an impact on the findings. In future updates, we
will explore the impact of the level of bias through undertaking
sensitivity analyses (Sensitivity analysis).
Assessment of the quality of the evidence using the
GRADE approach
For this update of the review, we used the GRADE approach, as
outlined in the GRADE handbook (GRADE 2013), to assess the
quality of the body of evidence relating to the following outcomes
for themain comparisons, progesterone versus placebo or no treat-
ment.
1. Miscarriage
2. Preterm birth
3. Congenital abnormalities
We used the GRADEpro Guideline Development tool (
GRADEpro GDT 2015) to import data from Review Manager 5
(RevMan 5) (RevMan 2014) in order to create ’Summary of find-
ings’ tables.We produced a summary of the intervention effect and
using the GRADE approach, a measure of quality for each of the
above outcomes. The GRADE approach uses five considerations
(study limitations, consistency of effect, imprecision, indirectness
and publication bias) to assess the quality of the body of evidence
for each outcome. The evidence can be downgraded from ’high
quality’ by one level for serious (or by two levels for very serious)
limitations, depending on assessments for risk of bias, indirectness
of evidence, serious inconsistency, imprecision of effect estimates
or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we present results as summary risk ratio
(RR) with 95% confidence intervals (CIs).
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Continuous data
None of the outcomes were reported as continuous data in this
update. In future updates, if trials measure outcomes in the same
way, we will use the mean difference. We will use the standardised
mean difference to combine trials that measure the same outcome,
but use different methods.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion. If
we identify any cluster-randomised trials in future updates of this
review, we will include them in the analyses along with individu-
ally randomised trials. We will adjust their sample sizes using the
methods described in the Cochrane Handbook for Systematic Re-
views of Interventions, using an estimate of the intra-cluster corre-
lation co-efficient (ICC) derived from the trial (if possible), from
a similar trial or from a study of a similar population (Higgins
2011c). If we use ICCs from other sources, we will report this and
conduct sensitivity analyses to investigate the effect of variation in
the ICC. If we identify both cluster-randomised trials and individ-
ually-randomised trials, we plan to synthesise the relevant infor-
mation. Wewill consider it reasonable to combine the results from
both if there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Dealing with missing data
For included trials, we noted levels of attrition. For all outcomes,
we carried out analyses, as far as possible, on an intention-to-treat
basis, that is, we attempted to include all participants randomised
to each group in the analyses, and analysed all participants in
the group to which they were allocated, regardless of whether or
not they received the allocated intervention. The denominator for
each outcome in each trial was the number randomised minus any
participants whose outcomes were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² (Higgins 2003) and Chi² statistics (Deeks 2011). We
regarded heterogeneity as substantial if I² was greater than 30%
and either Tau² was greater than zero, or there was a low P value
(less than 0.10) in the Chi² test for heterogeneity.
Assessment of reporting biases
In future updates of this review, if there are 10 or more trials in the
meta-analysis we will investigate reporting biases (such as publica-
tion bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it (Sterne 2011).
Data synthesis
We carried out statistical analysis using the RevMan 5 software
(RevMan 2014). We used fixed-effect meta-analysis for combin-
ing data where it was reasonable to assume that trials were esti-
mating the same underlying treatment effect: that is, where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. In future updates,
if there is clinical heterogeneity sufficient to expect that the un-
derlying treatment effects would differ between trials, or if we de-
tect substantial statistical heterogeneity, we will use random-ef-
fects meta-analysis to produce an overall summary, if an average
treatment effect across trials is considered clinically meaningful.
We will treat the random-effects summary as the average range of
possible treatment effects and we will discuss the clinical implica-
tions of treatment effects differing between trials. If the average
treatment effect is not clinically meaningful we will not combine
trials (Deeks 2011).
If we use random-effects analyses, we will present the results as the
average treatment effect with 95% CIs, and the estimates of Tau²
and I².
Subgroup analysis and investigation of heterogeneity
Wedid not identify substantial heterogeneity.However, we carried
out the following subgroup analyses for the primary outcome.
1. Route of administration
If we identify substantial heterogeneity in future updates of this
review, we will investigate it using subgroup analyses and sensi-
tivity analyses. We will consider whether an overall summary is
meaningful, and if it is, use random-effects analysis to produce it.
We will include the following subgroups, in addition to route of
administration.
1. Type of progestogen
2. Progestogen dose
3. Effect of progestogens in early (no more than 12 weeks) and
late (more than 12 weeks) threatened miscarriage
Wewill restrict subgroup analysis to the primary outcome.Wewill
assess subgroup differences by interaction tests available within
RevMan 5 (RevMan 2014).We will report the results of subgroup
analyses quoting the Chi² statistic and P value, and the interaction
test I² value (Deeks 2011).
Sensitivity analysis
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We included seven trials in this review. All but one were similar
in terms of risk of bias. For future updates of this review, we will
carry out sensitivity analysis to explore the effect of risk of bias.
This will involve analysis based on our ’Risk of bias’ judgements
for allocation concealment, performance bias and attrition bias.
We will compare the results of those trials assessed as being rated
’low’ risk of bias for these domains with those rated as ’high’ or
’unclear’ risk of bias.
R E S U L T S
Description of studies
Results of the search
We assessed 29 new trial reports of potential relevance identified
by the updated search (see: Figure 1).
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Figure 1. Trial flow diagram
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Included studies
Trial location
We included seven trials (involving 696 participants) in this up-
date of the review. The included trials were conducted in differ-
ent countries, covering the full spectrum of theWorld Bank’s eco-
nomic classification (World Bank 2017), which may enhance the
applicability and generalisation of evidence drawn from this re-
view. Two trials were conducted in Germany and Italy (Gerhard
1987; Palagiano 2004), which are high-income countries, while
four trials were conducted in upper-middle income countries;
two in Iran (Alimohamadi 2013; Yassaee 2014), one in Malaysia
(Pandian 2009) and the fourth in Turkey (Turgal 2017). The sev-
enth trial was conducted in Jordan (El-Zibdeh 2009), which is a
lower-middle income country. All trials were conducted in hospi-
tal settings.
Trial design
We included six randomised controlled trials (Alimohamadi
2013; Gerhard 1987; Palagiano 2004; Pandian 2009; Turgal
2017; Yassaee 2014) and one quasi-randomised controlled trial
(El-Zibdeh 2009).
Sample size
A total of 696womenwere included in this review. The largest trial
involved 191 women (Pandian 2009) and the smallest involved
35 women (Gerhard 1987).
Participants
We included pregnant women, with threatened miscarriage at or
less than 23 weeks and who had a confirmed viable pregnancy.
Fetal viability was to ensure that we excluded from this review
trials that included women with bleeding in early pregnancy due
to missed miscarriage. We placed no restriction on the age of the
woman or past obstetric history.
Type of intervention
The seven included trials compared progestogens to either placebo
(Alimohamadi 2013; Gerhard 1987; Palagiano 2004; Turgal
2017) or no treatment (El-Zibdeh 2009; Pandian 2009; Yassaee
2014). Three trials investigated oral progestogen (El-Zibdeh 2009;
Pandian 2009; Turgal 2017) and four investigated vaginal pro-
gesterone (Alimohamadi 2013; Gerhard 1987; Palagiano 2004;
Yassaee 2014).
Outcome measure
Primary outcome
Miscarriage
All the included trials investigated this primary outcome.Three tri-
als investigated oral progestogen (El-Zibdeh 2009; Pandian 2009;
Turgal 2017), and four trials investigated vaginal progesterone
(Alimohamadi 2013; Gerhard 1987; Palagiano 2004; Yassaee
2014).
Secondary outcomes
Pain relief
Two trials (Palagiano 2004; Yassaee 2014) reported pain relief as
an outcome of treatment with progesterone.
Preterm birth
Five trials (Alimohamadi 2013; El-Zibdeh 2009; Gerhard 1987,
Pandian 2009; Turgal 2017); with 588 women, reported the effect
of oral or vaginal progestogens on preterm birth.
Pregnancy-induced hypertension
Two trials (El-Zibdeh 2009; Pandian 2009) reported pregnancy-
induced hypertension as a maternal adverse outcome.
Antepartum haemorrhage
Two trials (El-Zibdeh 2009; Pandian 2009) reported antepartum
haemorrhage as a maternal adverse outcome.
Perinatal death
One trial investigated the effect of progestogens on neonatal death
(Alimohamadi 2013) and two trials investigated the effect of pro-
gestogens on stillbirth (Pandian 2009; Turgal 2017).
13Progestogen for treating threatened miscarriage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Congenital abnormalities
Two trials (El-Zibdeh 2009; Pandian 2009) reported congenital
abnormalities as an outcome.
Intrauterine growth restriction and low birthweight
Two trials (Turgal 2017, El-Zibdeh 2009) reported on the fre-
quency of intrauterine growth restriction in the intervention and
control groups. Another trial (Alimohamadi 2013) reported on the
frequency of low birthweight in the progesterone and the placebo
group.
Respiratory distress syndrome
One trial (Alimohamadi 2013) investigated the rate of respiratory
distress syndrome in the progesterone and the placebo group.
Birthweight
Only one trial (Turgal 2017) reported the difference in birthweight
as an outcome.
Date of trials
Six trials were published between 2004 and 2017 (Alimohamadi
2013; El-Zibdeh 2009; Palagiano 2004; Pandian 2009; Turgal
2017; Yassaee 2014). One trial was published in 1987 (Gerhard
1987).
Funding source
Solvay Pharmaceuticals funded two trials (El-Zibdeh 2009;
Pandian 2009). The rest of the trials did not mention the source
of funding.
Delcaration of interest
None of the study authors reported any conflict of interest.
For further details, see Characteristics of included studies.
Excluded studies
In this update of the review, we excluded 10 (plus two dupli-
cate) full-text trials, in addition to the 32 excluded from the pre-
vious version. The reasons for exclusion of the 42 trials was as
follows: 18 trials had a different population to this review’ cri-
teria (Brenner 1962; Corrado 2002; El Zibdeh 2000; El Zibdeh
2002; El Zibdeh 2005; Fuchs 1966; Goldzieher 1964; Johnson
1975; Klopper 1965; Le Vine 1964; Nyboe 2002; Porcaro 2015;
Prietl 1992; Reijnders 1988; Shearman 1963; Smitz 1992; Swyer
1953; Turner 1966); 14 trials, either compared progesterone to
another type of progesterone or used it in combination with an-
other therapy (Beigi 2016; Berle 1977; Check 1995; Chye 2014
(and duplicate); Czajkowski 2007; Famina 2015; Hui 2015; Luz
1988 [pers comm]; Pustotina 2018; Siew 2014; Siew 2015; Song
2007; Vincze 2006; Zhang 2000); seven trials did not use a reliable
method to confirm the viability of the fetus (Berle 1980; Crowder
1950; Govaerts-Videtzky 1965; Moller 1965; Sondergaard 1985;
Souka 1980; Tognoni 1980); one study (and duplicate) had a
mixed group of participants and we could not obtain separate re-
sults for the threatened-miscarriage group (Costantino 2016); one
was not an RCT (Akhtar 2012); and one study had a high rate of
attrition, more than 20% (Omar 2005).
For further details, see Characteristics of excluded studies.
Risk of bias in included studies
(Figure 2, Figure 3)
14Progestogen for treating threatened miscarriage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials
We judged only three of the seven included trials (42%) to be at
low risk of bias for random sequence generation and allocation
concealment, and four trials (57%) to be at low risk for perfor-
mance bias. We judged all trials (100%) at low risk of detection
bias and attrition bias. We judged six trials at low risk of selective
reporting bias (85%), and five trials (71%) at low risk of other
biases.
Allocation
In three trials (Alimohamadi 2013; Pandian 2009; Turgal 2017),
the investigators described a random component in the sequence-
generation process by using computer random-number genera-
tors, so we judged these trials to have low risk of selection bias. In
three trials (Gerhard 1987; Palagiano 2004; Yassaee 2014), there
was insufficient information about the sequence-generation pro-
cess to permit judgement of low or high risk, so we judged them
as unclear risk of selection bias. We judged one study (El-Zibdeh
2009) as high risk for selection bias, as the investigators described
a non-random component in the sequence-generation process,
which was based on the day of the week that women presented to
the clinic.
Participants and investigators enrolling participants could not
foresee assignment to intervention or control group in three trials
because Alimohamadi 2013 and Palagiano 2004 used sequentially
numbered drug containers of identical appearance and Pandian
2009 used sequentially numbered concealed envelopes; we judged
these trials at low risk of selection bias. Three trials (Gerhard 1987;
Turgal 2017; Yassaee 2014), did not describe the method of con-
cealment sufficiently to allow a definite judgement, so we judged
them at unclear risk of selection bias. In El-Zibdeh 2009, partici-
pants and investigators enrolling participants could foresee assign-
ments, as the allocation was performed by the attending physician
based on the day of the week the women visited the clinic, and
thus the risk of selection bias introduction was high.
Blinding
Four trials (Alimohamadi 2013; Gerhard 1987; Palagiano 2004;
Turgal 2017) ensured blinding of participants and key study per-
sonnel, and it is unlikely that the blinding could have been broken,
so we judged the risk of performance bias to be low. Three trials
did not use placebo for the control group. Two of these (El-Zibdeh
2009; Pandian 2009) did not blind either personnel or women to
the treatment received and one (Yassaee 2014) was a single-blind
study, in which the researchers were unaware which woman had
received progesterone. Although outcomes such as miscarriage,
preterm birth and fetal structural malformations are not likely to
be influenced by lack of blinding, lack of blinding of participants
or personnel could have introduced performance bias if partici-
pants inadvertently took a different type of progestogen than the
one in the trial or exaggerated their reports of subjective outcomes,
such as pain.
Five of the seven trials blinded outcome assessors to the treatment
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the women had received (Alimohamadi 2013; El-Zibdeh 2009;
Gerhard 1987; Palagiano 2004; Yassaee 2014). Pandian 2009 did
not blind the assessors, and Turgal 2017 did not give any informa-
tion about blinding. Outcomes such as miscarriage, preterm birth
and fetal structural malformations are not likely to be influenced
by lack of assessor’s blinding, so we judged all seven trials as having
low risk of detection bias.
Incomplete outcome data
There was no missing outcome data in five of the seven in-
cluded trials (Alimohamadi 2013; El-Zibdeh 2009; Palagiano
2004; Pandian 2009; Yassaee 2014); Gerhard 1987 excluded two
women (5.7%) from the study after randomisation, and Turgal
2017 reported incomplete outcome data for 12 women (14.5%),
equal in both groups. We judged all seven trials to be at low risk
of attrition bias.
Selective reporting
All the included trials, except one (Palagiano 2004), reported all
of the expected prespecified (primary and secondary) outcomes,
so we assessed these at low risk of reporting bias. In Palagiano
2004, the study authorsmentioned in themethods that theywould
report all the adverse effects, but in the results there was no explicit
mention of the absence or presence of any adverse effects, so we
judged it to be at high risk of reporting bias.
Other potential sources of bias
We assessed one study at high risk of other biases due to the differ-
ence in the number of participants recruited to the experimental
and the control groups (86 versus 60; El-Zibdeh 2009). In an-
other study (Gerhard 1987), the risk of other bias was not clear
because we included only participants with evidence of fetal via-
bility, which amounts to only half of the participants.
Effects of interventions
See: Summary of findings for the main comparison
Progesterone compared to placebo or no treatment for treating
threatened miscarriage
Seven trials met the inclusion criteria, involving 696 participants.
We performed subgroup analysis for the effect of progestogens by
route of administration; however, due to paucity of data we could
not carry out subgroup analysis for type and dose of progestogen.
We undertook a total of six meta-analyses.
Primary outcome
Miscarriage
The seven included trials, with 696 participants, compared pro-
gestogens to either placebo (Alimohamadi 2013; Gerhard 1987;
Palagiano 2004: Turgal 2017) or no treatment (El-Zibdeh 2009;
Pandian 2009; Yassaee 2014). Treatment of miscarriage with pro-
gestogens compared to placebo or no treatment probably reduces
the risk of miscarriage; (risk ratio (RR) 0.64, 95% confidence in-
terval (CI) 0.47 to 0.87; 7 trials; 696 women; moderate-quality
evidence).
Subgroup analysis by route of administration
Three trials investigated treatment with oral progestogen (El-
Zibdeh 2009; Pandian 2009; Turgal 2017), and showed that treat-
ment with oral progestogen compared to no treatment probably
reduces the miscarriage rate (RR 0.57, 95% CI 0.38 to 0.85; 3 tri-
als; 408 women; moderate-quality evidence; Analysis 1.1.1). Four
trials investigated treatment with vaginal progesterone compared
to placebo (Alimohamadi 2013; Gerhard 1987; Palagiano 2004;
Yassaee 2014), which probably has little or no effect in reducing
the miscarriage rate (RR 0.75, 95% CI 0.47 to 1.21; 4 trials; 288
women; moderate-quality evidence; Analysis 1.1.2). However, It
should be noted that there were no differences between these two
subgroups according to the subgroup interaction test (test for sub-
group differences: Chi² = 0.76, df = 1 (P = 0.38), I² = 0%).
Secondary outcomes
Maternal outcomes
Pain relief
Two trials (Palagiano 2004; Yassaee 2014) reported pain relief as an
outcome of treatment with progesterone. Palagiano 2004 reported
reduction on the mean pain score with the use of progesterone
from 2.6 ± 0.9 before treatment to 0.4 ± 0.7 (mean ± standard
deviation) after treatment (P < 0.01), while no change in pain
score was observed in women who received placebo from 2.5 ±
1.0 before treatment to 2.4 ± 0.8 (mean ± standard deviation)
after treatment (P > 0.05). They reported pain using a progressive
score from 0 to 4, where a score of 0 indicated ’no pain’ and a
score of 4 indicated ’extreme pain’. In Yassaee 2014, nine (30%) of
the women in the progesterone and seven (23.3%) of the control
group, continued to have pain after intervention (P = 0.55). We
could not pool the results of these two trials due to the different
types of data (dichotomous and continuous).
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Preterm birth
Five trials (Alimohamadi 2013; El-Zibdeh 2009; Gerhard 1987,
Pandian 2009; Turgal 2017); reported the effect of progestogens
on preterm birth. Treatment of preterm birth with the use of
progestogens compared to placebo or no treatment may have little
or no effect in reducing the rate of pretermbirth (RR0.86, 95%CI
0.52 to 1.44; 5 trials; 588 women; low-quality evidence; Analysis
1.2).
Other maternal adverse outcomes
Pregnancy-induced hypertension
Two trials (El-Zibdeh 2009; Pandian 2009) reported pregnancy-
induced hypertension as a maternal adverse outcome. There was
no difference in the occurrence of pregnancy-induced hyperten-
sion between the progestogen and the control group (RR 1.00,
95% CI 0.54 to 1.88; 2 trials; 337 women; Analysis 1.3).
Antepartum haemorrhage
Two trials (El-Zibdeh 2009; Pandian 2009) reported antepartum
haemorrhage as maternal adverse outcome. Progestogens have lit-
tle or no difference in the occurrence of antepartum haemorrhage
(RR 0.76, 95% CI 0.30 to 1.94; 2 trials; 337 women; Analysis
1.4).
Child outcomes
Stillbirth
Two trials investigated the effect of progestogens on the stillbirth
rate (Pandian 2009; Turgal 2017). Progestogens have little or no
difference effects on the rate of stillbirth (RR 1.94, 95% CI 0.18
to 20.49; 2 trials; 262 women; Analysis 1.5).
Congenital abnormalities
Two trials (El-Zibdeh 2009; Pandian 2009) reported congenital
abnormalities as an outcome. We are uncertain if treatment of
threatened miscarriage with progestogens compared to placebo or
no treatment has any effect on the rate of congenital abnormalities,
(RR 0.70, 95% CI 0.10 to 4.82; 2 trials; 337 infants; very low-
quality evidence; Analysis 1.6).
Neonatal death
Only one trial reported the effect of progestogens on neonatal
death (Alimohamadi 2013). Progestogens have little or no effect
in the neonatal death rate (RR 1.35, 95% CI 0.31 to 5.83; 1 trial;
145 women).
Other neonatal adverse outcomes
Intrauterine growth restriction and low birthweight
One trial (Turgal 2017) reported on the frequency of intrauter-
ine growth restriction in the intervention and control group and
showed no difference between the two groups; 0 (0%) in the pro-
gestogen group, one (3.5%) in the control group. Another trial
(Alimohamadi 2013) reported on the frequency of lowbirthweight
in the progesterone and the placebo group and showed no dif-
ference between the two groups; five (7%) for the progesterone
group and seven (9.8%) for the placebo group.
Birthweight
Only one trial (Turgal 2017) reported the difference in birthweight
as an outcome. It showed no difference in the mean birthweight
between the progestogen and the control group; 3.1156 ± 0.643 kg
for the intervention group and 3.2076 ± 0.500 kg for the control
group.
Respiratory distress syndrome
One trial (Alimohamadi 2013) investigated the rate of respiratory
distress syndrome in the progesterone and the placebo groups,
and showed no difference between the two groups; there were
two neonates with respiratory distress syndrome (2.8%) in the
progesterone group and one (1.4%) in the placebo group.
Outcomes not reported in the primary trials
Due to paucity of data, we could not evaluate the following sec-
ondary outcomes.
1. Thromboembolism
2. Depression
In additionwe could not perform the following subgroup analyses.
1. Route of progestogen administration
2. Type of progestogen
3. Progestogen dose
4. Effect of progestogens in early and late miscarriage
D I S C U S S I O N
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Summary of main results
We included seven trials (involving 696 participants) in this up-
date of the review. The included trials were conducted in differ-
ent countries, covering the full spectrum of theWorld Bank’s eco-
nomic classification (World Bank 2017), which enhances the ap-
plicability of evidence drawn from this review. Two trials were con-
ducted in Germany and Italy which are high-income countries,
while four trials were conducted in upper-middle income coun-
tries; two in Iran, one in Malaysia and the fourth in Turkey, and
the seventh trial was conducted in Jordon, which is a lower-middle
income country. In six trials all the participants met the inclusion
criteria and in the seventh study, we included only the subgroup
of participants who met the inclusion criteria in the meta-analy-
sis. Using the GRADE tool, we assessed the body of evidence for
the main outcomes as ranging from very low-quality to moderate-
quality evidence. Downgrading of evidence was based on the high
risk of bias in six of the seven included trials and imprecision for
some of the outcomes.
Treatment of miscarriage with progestogens compared to placebo
or no treatment probably reduces the risk of miscarriage. Sub-
group analysis by route of administration showed that treatment
with oral progestogen compared to no treatment probably reduces
themiscarriage rate, although treatment with vaginal progesterone
compared to placebo, probably has little or no effect in reduc-
ing the miscarriage rate. However, the subgroup interaction test
indicated no difference according to route of administration be-
tween the oral and vaginal subgroups of progesterone. Treatment
of pretermbirth with the use of progestogens compared to placebo
or no treatment may have little or no effect in reducing the rate
of preterm birth. We are uncertain if treatment of threatened mis-
carriage with progestogens compared to placebo or no treatment
has any effect on the rate of congenital abnormalities.
Overall completeness and applicability of
evidence
Threatened miscarriage is a common health problem. In a longi-
tudinal study by Blohm 2008, one in four multiparous women
had experienced a miscarriage and more than 7% of the stud-
ied population had experienced three or more miscarriages. In a
large population-based study by Cohain 2017, more than 40%
of parous women reported having experienced one or more first
trimester spontaneous miscarriages.
This update of the review includes seven trials, with a relatively
small number of women (696), from six countries. All trials were
conducted in hospital settings. Two trials were conducted in high-
income countries (Gerhard 1987; Palagiano 2004), four in up-
per-middle income countries (Alimohamadi 2013; Pandian 2009;
Turgal 2017; Yassaee 2014) andone in lower-middle income coun-
try (El-Zibdeh 2009). Although no trial was conducted in a low-
income country, the participants in the trials of the review have
diverse ethnic and economic backgrounds (World Bank 2017).
This may make the evidence in this review applicable to a large
sector of women with threatened miscarriage.
Quality of the evidence
In this updated review we assessed the body of evidence for mis-
carriage as moderate quality, mainly due to limitations in study
design of the included trials. From the seven included trials we
judged only three (42%) to be at low risk of bias for random se-
quence generation and allocation concealment. Four trials (57%)
were at low risk for performance bias, and all were at low risk of
detection bias. We assessed all trials at low risk for attrition bias
and six were at low risk of selective reporting bias. Only five trials
(71%) trials were at low risk for other biases (Summary of findings
for the main comparison).
For preterm birth we assessed the body of evidence as low quality
due to imprecision (wide confidence intervals crossing the no-
effect line) and limitations with study design of the included trials.
From the five included trials, three (60%)were at low risk of bias for
random sequence generation, while three (60%)were at low risk of
performance bias and all trials were at low risk of detection bias. In
addition, one study randomised different numbers of participants
to the two arms of the study, which we considered as additional
bias and in one study we included the results of only 50% of the
participants who met the inclusion criteria.
For the outcome congenital abnormality, we assessed the body of
evidence as very low due to imprecision (wide confidence intervals
crossing the no-effect line), small number of trials (two trials) and
participants (337 women) and limitations with study design. We
assessed one of the two included trials to be at high risk of selection
bias and performance bias and the other study at high risk of
performance bias.
Potential biases in the review process
In this review, we took steps to minimise bias, although we are
aware that bias may be present in our review: two review authors
independently assessed trials for eligibility and extracted the data
as necessary. We resolved discrepancies through discussion or, if
required, we consulted a third review author; two review authors
also performed GRADE assessments independently and resolved
discrepancies though discussion; and we conducted a comprehen-
sive search in order to identify all relevant published and unpub-
lished literature.
Agreements and disagreements with other
studies or reviews
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Our assessment of the body of evidence in this update of the re-
view did not differ much from the previous version of the re-
view (Wahabi 2011). For the main comparison, we have included
three additional trials, however, neither the magnitude nor the di-
rection of evidence changed markedly from the earlier version of
the review. We have used the recent methodology introduced for
Cochrane Reviews in 2008, which assesses risk of bias in the indi-
vidual trials more carefully than in the past (Higgins 2011b). In
addition, we assessed the quality of the evidence using theGRADE
approach as outlined in the GRADEHandbook (GRADE 2013).
The results of this review agree with a recently published system-
atic review of randomised and non-randomised controlled trials of
dydrogesterone (oral progestogen) for the treatment of threatened
miscarriage (Carp 2012) and with non-randomised controlled tri-
als (Akhtar 2012), which investigated the effectiveness of oral pro-
gestogens in the treatment of threatenedmiscarriage. The results of
this trial showed that a larger proportion of women who received
progestogen continued to be pregnant compared to the control
group, however, the difference was not significant.
Recently published trials suggested that the route of administration
and the type of progestogen influence its effectiveness in the pre-
ventionofmiscarriage. In amulticenter, randomised, placebo-con-
trolled trial on women with unexplained recurrent miscarriages,
vaginal progesterone was found not to be significantly different
from placebo in the prevention of miscarriage (Coomarasamy
2015). However, the results of a review of randomised trials on the
use of progestogen in the prevention of recurrent miscarriage, con-
cluded that synthetic progestogens, but not natural progesterone,
were associated with a lower risk of recurrent miscarriage, never-
theless, the conclusion was limited by the low quality of evidence
(Saccone 2017).
Our results suggested that progestogen may not be as effective
in the prevention of preterm birth (Analysis 1.2). There are con-
flicting published reports about the effectiveness of progestational
agents in the prevention of preterm birth with apparent influ-
ence of type of progestogen and route of administration, as well as
different subgroups of women, on the effectiveness of treatment
(Facchinetti 2017; Heyborne 2016; O’Brien 2016).
Our results relating to the safety of progestogen use for themother
and infant are limited by the small number of trials and partici-
pants in addition to the low quality of the evidence. However, our
systematic review is in agreement with other systematic reviews,
which also suggest that there are no increased risks of adverse out-
comes to the mother or the infant from the use of progestogen
compared to the control group (Haas 2018).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results of this review suggest that progestogens are probably
effective in the treatment of threatened miscarriage but may have
little or no effect in the rate of preterm birth. The evidence on
congenital abnormalities is uncertain, because the quality of the
evidence for this outcome was based on only two small trials with
very few events and was found to be of very low quality.
Implications for research
Further research could investigate the effectiveness and safety of
progestogens in the treatment of threatened miscarriage by con-
ducting methodologically sound, randomised trials, with special
focus on the type of progestogen and the route of administration.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alimohamadi 2013
Methods Design: RCT, double-blind, placebo-controlled, parallel-group
Recruitment method: unclear
Method of randomisation: computer-generated block randomisation
Setting: Obstetrics and Gynaecology ward of Vali-e-Asr teaching hospital in Tehran
Participants Inclusion: pregnant women with clinical symptoms of threatened abortion before 20th
week of pregnancy
Exclusion: women with systemic diseases, including maternal hypertension before or
during pregnancy, cardiac disease, renal disease, genital tract anomalies of the mother or/
and diabetes. Women with uterine tenderness, congenital defects of the fetus, and those
who had used a progestational drug during pregnancy, prior to being recruited into the
study
Particpants randomised: 160
Interventions Intervention group: (80 women) vaginal progesterone, 200 mg twice daily for 1 week
Control group: (80 women) placebo with the same description and duration of treat-
ment as experimental group
Outcomes Endocervical concentrations of different cytokines
Miscarriage
Preterm delivery
Neonatal death
Low birth weight
Respiratory distress syndrome
Notes Journal: Journal of Reproductive Immunology
Year of publication: 2013
Country: Iran
Income status of the country: upper-middle-income
Source of funding: not mentioned
Conflict of interest: no conflict of interest
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated block randomisation
Allocation concealment (selection bias) Low risk Pharmacy prepared
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and clinicians were unaware of
allocation
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Alimohamadi 2013 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data of 15 partici-
pants (9.4%); 8 in intervention and 7 in
control groups (balanced attrition)
Selective reporting (reporting bias) Low risk All outcomes were reported
Other bias Low risk No other risk of biases
El-Zibdeh 2009
Methods Design: quasi-experimental
Recruitment method: pregnant women consecutively presented to the clinic during
study period
Method of randomisation: according to the day of the week the women attended
the clinic; women attending on Saturday, Monday, and Wednesday were assigned to
intervention group and those attending on Sunday, Tuesday, and Thursday were assigned
to the control group
Setting: Amman Islamic Hospital clinic
Participants Inclusion: women with threatened miscarriage (mild or moderate vaginal bleeding dur-
ing the first trimester of pregnancy)
Exclusion: presence of a systemic illness or fever, the suspected passage of any fetal or
pregnancy materials, and the absence of a normal gestational sac at 5 weeks gestational
age, a yolk sac at 5.5-6 weeks gestational age, an embryo at 6-6.5 weeks gestational age
or cardiac activity at 7 weeks gestational age
Particpants randomised: 146
Interventions Intervention group: (86 women) synthetic progesterone, dydrogesterone, oral 10 mg
twice daily. Until 1 week after the bleeding stopped. Standard supportive care, including
iron, folic acid and multivitamin supplements and bed rest
Control group: (60 women) no treatment. Standard supportive care, including iron,
folic acid and multivitamin supplements and bed rest
Outcomes Miscarriage
Preterm delivery
Fetal structural malformations, including genital malformations
Maternal hypertension
Intra-uterine growth restriction
APH
Notes Journal: Maturitas
Year of publication: 2009
Country: Jordan
Income status of the country: lower-middle-income
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El-Zibdeh 2009 (Continued)
Source of funding: Solvay Pharmaceuticals
Conflict of interest: no actual or potential conflict
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk According to the day of the week the
women presented to the clinic. Women at-
tending the clinic on Saturday, Monday or
Wednesday were allocated to the interven-
tion group and those attending on Sunday,
Tuesday or Thursday were allocated to the
control group
Allocation concealment (selection bias) High risk The randomisation was performed by the
attending physician, who also gave the
treatment to the women
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of the participants and study
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was ensured for the outcome as-
sessors.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) Low risk All the prespecified outcomes were ad-
dressed.
Other bias High risk The difference in the number of partic-
ipants recruited to experimental and the
control groups (86 versus 60) might have
introduced bias
Gerhard 1987
Methods Design: RCT, double-blind
Recruitment method: women with vaginal bleeding were referred to the hospital
Method of randomisation: unclear
Setting: Women’s Hospital, University of Heidelberg
Participants Inclusion: vaginal bleeding and the internal cervical os being closed
Exclusion: none
Particpants randomised: 35
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Gerhard 1987 (Continued)
Interventions Intervention group: (17 women) 1 vaginal suppository twice daily, containing 25 mg
progesterone, and bed rest
Control group: (18 women) 1 vaginal suppository twice daily, containing polyethylene
glycol, and bed rest
Outcomes Miscarriage
14 days of being symptom free
Preterm delivery
Notes Journal: Biological Research in Pregnancy
Year of publication: 1987
Country: Germany
Income status of the country: high-income
Source of funding: not mentioned
Conflict of interest: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation was not
mentioned
Allocation concealment (selection bias) Unclear risk Themethod of allocation concealment was
not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants and study person-
nel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of the outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 women (5.7%) were omitted from the
study after randomisation
Selective reporting (reporting bias) Low risk All the prespecified outcomes were ad-
dressed
Other bias Unclear risk As we included only participants with evi-
dence of fetal viability, which amounted to
only half the participants, we are unclear
how much bias was introduced
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Palagiano 2004
Methods Design: RCT
Recruitment method: unclear
Method of randomisation: unclear
Setting: a medical centre
Participants Inclusion: women with threatened abortion; viable baby; amenorrhoea 6-12 weeks;
closed uterine cervix
Exclusion: women with previous adequate luteal phase; women who were using hor-
monal treatment or other drugs affecting uterine contractility; women with vaginal in-
fection; absence of embryo’s heartbeat; open cervix (> 2 cm measured by U/S); embryo’s
size 1 week more than the corresponding amenorrhoea
Particpants randomised: 50
Interventions Intervention group: (25 women) 90 mg vaginal progesterone once daily for 5 days
Control group: (25 women) placebo
Outcomes Pain score
Uterine contractility
Abortion rate
(Followed for 60 days for the occurrence of miscarriage and for 5 days for the other
outcomes)
Notes Journal: Annals New York Academy of Sciences
Year of publication: 2004
Country: Italy
Income status of the country: high-income
Source of funding: not mentioned
Conflict of interest: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk This is a randomised trial but the method
of randomisation wan not mentioned
Allocation concealment (selection bias) Low risk Code numbers were attached to each con-
tainer of the gel. The researcher recorded
the progressive number of the container
given to the patients enrolled, who received
a correspondent code. Only 3 months af-
ter the end of the database recording, the
codes were open and showed to the Data
Monitoring Board (DMB) to be evaluated
by a statistician
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and study personnel were
blinded
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Palagiano 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The effect on pain symptom amelioration
was evaluated by a 5-score intensity grad-
ing, whereas uterine contractionswere eval-
uated by standard transvaginal ultrasound,
the code was broken only after the analysis
by the statistician
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up
Selective reporting (reporting bias) High risk In the methods study authors mentioned
they will report all adverse effects, but there
was no explicit mention of the absence or
presence of any adverse effects in the results
section
Other bias Low risk No risk of other biases
Pandian 2009
Methods Design: RCT
Recruitment method: all women presenting with vaginal bleeding up to 16 weeks of
pregnancy were assessed for inclusion
Method of randomisation: sealed envelopes picked by the participants
Setting: Department of Obstetrics and Gynaecology, Seberang Jaya Hospital
Participants Inclusion: women with threatened abortion. Viability of fetus confirmed by U/S. no
systematic illness or fever and no loss of conception tissue
Exclusion: women with recurrent miscarriage (> 3), heavy bleeding, cervical polyp,
multiple gestation, empty sac > 26 mm
Particpants randomised: 191 women
Interventions Intervention group: (96 women) 40 mg followed by 10 mg twice daily
Control group: (95 women) conservative treatment with bed rest only
Outcomes Miscarriage rate
Placenta previa
Preterm delivery
Congenital anomalies
APH
Caesarean section
Low birth weight
Preganancy induced hypertension
Perinatal death
Notes Journal: Maturitas
Year of publication: 2009
Country: Malaysia
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Pandian 2009 (Continued)
Income status of the country: upper middle-income
Source of funding: Solvay Pharmaceutical Company
Conflict of interest: no conflicts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation of each women using
sealed envelope
Allocation concealment (selection bias) Low risk Concealed envelope
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and the study personnel were
not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only the statistician was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no loss of follow-up
Selective reporting (reporting bias) Low risk All the prespecified outcomes were ad-
dressed
Other bias Low risk No apparent other sources of bias
Turgal 2017
Methods Design: RCT
Recruitment method: through assessment of women presented to the hospital
Method of randomisation: computerised random number generator program
Setting: a university hospital
Participants Inclusion: women with threatened abortion and with presence singleton pregnancy and
live embryo, before 9 weeks of gestation
Exclusion: non viable fetus, twin pregnancy, presence of subchorionic haematoma and
history of hypertension, diabetes mellitus, severe hepatic disorders, uterine leiomyoma,
congential uterine anomaly and recurrent pregnancy loss
Particpants randomised: 83
Interventions Intervention group: (42 women) oral micronised progesterone, 400 mg/d for 4 weeks
Control group: (41 women) placebo
Outcomes Primary outcome:
• fetal-placental volume change
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Turgal 2017 (Continued)
Secondary outcomes:
• miscarriage rate
• live birth rate
• preterm birth
• birthweight
• LBW
• intrauterine growth restriction
• neonatal respiratory distress syndrome
Notes Journal: Journal of clinical Utrasound
Year of publication: 2017
Country: Turkey
Income status of the country: upper middle-income
Source of funding: not mentioned
Conflict of interest: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised random number by using
generator program
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo was used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome is not affected by blinding of out-
comes assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data in 12 women
(14.5%), equal in both groups
Selective reporting (reporting bias) Low risk All the prespecified outcomes were ad-
dressed
Other bias Low risk No other biases
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Yassaee 2014
Methods Design: RCT
Recruitment method: through assessment of women presented to the hospital
Method of randomisation: unclear
Setting: Taleghani Hospital affiliated to Shahid Beheshti University of Medical Sciences
Participants Inclusion: pregnant women with threatened abortion. The presence of singleton preg-
nancy and detection of fetal heart activity, besides gestational age of < 20 weeks was
verified by U/S
Exclusion: women were excluded if they had reaction to Cyclogest, repeated abortions,
multiple gestation, absence of fetus or fetal heart tone, uterine anomaly or fetal anomaly
Particpants randomised: 60 women
Interventions Intervention group: 400 mg of vaginal progesterone suppository (Cyclogest) each day
until their bleeding stopped in < 1 week
Control group: no treatment
Outcomes Successful delivery
Miscarriage rates
Pain relief
Notes Journal: Journal of Reproduction and Infertility
Year of publication: 2014
Country: Iran
Income status of the country: upper middle-income
Source of funding: not mentioned
Conflict of interest: no conflicts
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on random allocation
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk There was no placebo, so participants were
not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss of participants to follow-up
Selective reporting (reporting bias) Low risk All the prespecified outcomes were ad-
dressed
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Yassaee 2014 (Continued)
Other bias Low risk No apparent other risk of bias
APH: antepartum haemorrhage; LBW: low birthweight; RCT: randomised controlled trial; U/S: ultrasound
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Akhtar 2012 Not RCT
Beigi 2016 Comparing 2 types of progestogens
Berle 1977 Combination therapy of progesterone and oestrogen was used in this study
Berle 1980 Viability of the fetus was not confirmed before commencement of progesterone treatment
Brenner 1962 Different population
Check 1995 Combination therapy of progestogen and immunotherapy
Chye 2014 Compares 2 types of progestogens
Corrado 2002 Different population
Costantino 2016 Participants were mixed group of women with threatened abortion and subchorionic haematoma, results
of intervention cannot be obtained separately
Crowder 1950 Viability was not confirmed before the commencement of the study
Czajkowski 2007 The study compared 2 types of progestogen
El Zibdeh 2000 Different population. Population with recurrent miscarriage rather than threatened miscarriage
El Zibdeh 2002 Different population. Population with recurrent miscarriage rather than threatened miscarriage
El Zibdeh 2005 Different population. Population with recurrent miscarriage rather than threatened miscarriage
Famina 2015 Comparing 2 types of progestogens
Fuchs 1966 Different population. Patients with recurrent miscarriage not threatened miscarriage
Goldzieher 1964 Different population. Population with recurrent miscarriage rather than threatened miscarriage
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(Continued)
Govaerts-Videtzky 1965 Viability was not confirmed before the commencement of the study
Hui 2015 Comparing 2 types of progestogens
Johnson 1975 Different population. Progestogen was used for the prevention of miscarriage in women with recurrent
miscarriage or preterm delivery not threatened miscarriage
Klopper 1965 Different population. Progestogen was used for the prevention of miscarriage in women with recurrent
miscarriage not threatened miscarriage
Le Vine 1964 Different population. Progestogen was used for the prevention of miscarriage in women with recurrent
miscarriage not threatened miscarriage
Luz 1988 [pers comm] Combination therapy of progestogen and oestrogen was used in this study
Moller 1965 Viability was not confirmed before the commencement of the study
Nyboe 2002 Different population. Progestogen was used for the prevention of miscarriage rather than the treatment
of threatened miscarriage
Omar 2005 Loss to follow-up was more than 20%
Porcaro 2015 Different population
Prietl 1992 Different population. Progesterone was used for the prevention of miscarriage rather than the treatment
of threatened miscarriage in IVF patients
Pustotina 2018 Comparing 2 types of progestogens
Reijnders 1988 Different population. Progestogen was used for the prevention not the treatment of miscarriage
Shearman 1963 Different population. Progestogen was used for population with recurrent miscarriage not threatened
miscarriage
Siew 2014 Comparing 2 types of progestogen.
Siew 2015 Comparing 2 types of progestogens
Smitz 1992 Different population. Progestogen was used for the prevention of miscarriage rather than the treatment
of threatened miscarriage in IVF patients
Sondergaard 1985 Viability was not confirmed before the commencement of the study
Song 2007 Combination progestogen with vitamin E
Souka 1980 Viability was not confirmed before the commencement of the study
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(Continued)
Swyer 1953 Different population. Progestogen was used for population with recurrent miscarriage not threatened
miscarriage
Tognoni 1980 Viability was not confirmed before the commencement of the study
Turner 1966 Different population. The study participants do not have threatened miscarriage
Vincze 2006 Comparing 2 types of progesterone
Zhang 2000 Combination progesterone with vitamin E
IVF: in vitro fertilisation; RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Yadav 2015
Methods RCT
Participants 100
Interventions Dydrogesterone, 30 mg/d
Outcomes Serum levels of IL-6,TNF-alpha and IL-10 were measured at the time of admission, 10 days, 14 weeks
Abortion rate
Notes Only abstract is available, waiting response from trial authors
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
ACTRN12611000405910
Trial name or title Does usingprogesterone in threatenedmiscarriage increase the live birth rate? Supporting threatened outcomes
with progesterone
Methods RCT intervention model: parallel assignment. Blinding (masking use)
Participants 386 women age: ≥ 18
Inclusion criteria; threatened miscarriage, live intrauterine pregnancy; gestation < 10 weeks + 0 days
38Progestogen for treating threatened miscarriage (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ACTRN12611000405910 (Continued)
Interventions Intervention group: progesterone pessary 400 mg nightly, until 12 weeks + 0 days
Control group: placebo
Outcomes Primary outcome:
• live birth rate
Starting date Jan 2012
Contact information Dr Luke McLindon address Mater Mothers’ Hospital, Raymond Terrace, South Brisbane, Queensland, 4101
Notes
IRCT201012035294N
Trial name or title Clinical trial comparison of progesterone suppository and placebo on the concentration of cervical inflam-
matory cytokines in patients at risk of miscarriage
Methods Randomised, parallel, double-blinded study
Participants All women who are 20 weeks pregnant and who have been referred for pain or increased cervical secretion
and spotting are included in the study
Interventions Intervention group: progesterone suppository 400 mg twice/d for 1 week
Control group: placebo
Outcomes Primary
• miscarriage rate
Secondary
• measurement of cervical inflammatory cytokines
Starting date June 2006
Contact information Dr Sedigheh Hanustah Zadeh
Valiasr Hospital, Tehran University of Medical Sciences
Iran, Tehran
00982166581617
hantoushzadeh@tums.ac.ir
Notes
IRCT2015020217035N2
Trial name or title Effect of oral progesterone (dydrogesterone) on incidence of glucose intolerance in pregnant females with
threatened miscarriage
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IRCT2015020217035N2 (Continued)
Methods Allocation: randomised double blind placebo controlled trial.
Intervention model: parallel assignment.
Masking: triple (participant, care provider, investigator).
Primary purpose: treatment.
Participants A total of 100 women who are 14 weeks pregnant and presented with threatenedmiscarriage will be recruited.
Participants will be tested to exclude abnormal blood glucose level. Women will be randomised to have either
oral Dydrogesterone 10 mg twice daily or placebo for the control group
Inclusion criteria: singleton pregnancy, the absence of any systemic disease, age < 30 years, BMI < 25, no
history of stillbirth, no family history of diabetes, non-smoking,
Exclusion criteria: history of diabetes, gestational diabetes and other systemic diseases, any fetal abnormalities
on ultrasound examination, multiple pregnancy, and previous macrosomia
Interventions: oral administration of dydrogesterone 10 mg twice daily or placebo
Interventions Intervention group: oral dydrogesterone 10 mg twice daily
Control group: placebo
Outcomes Treatment of threatened miscarriage and preterm delivery
To study the effect of oral progesterone (dydrogesterone) on incidence of glucose intolerance in pregnant
women with threatened miscarriage
Starting date March 2015
Contact information Hafez Hospital
Shiraz
Fars
Iran, Islamic Republic Of
009871361222220
00989173138847
maryamkasraeian@gmail.com
Notes
IRCT2016040627248N1
Trial name or title The efficacy of a special food (fried egg with grape molasses) on threatened miscarriage: a randomised con-
trolled trial
Methods RCT, single-blind, no placebo
Participants 90 women
Inclusion criteria: pregnant women, (up to 12 weeks), presenting with mild-moderate vaginal bleeding with
normal U/S and closed cervix in vaginal examination; singleton pregnancy; and who consent to participate
in the study and are ready to consume the special food
Interventions Intervention group: in addition to intravaginal Cyclogest, the food recipe of fried eggs with butter and grape
molasses will be given to women. The other conditions of intervention group, including the duration of
eating this food, are similar to the control group
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IRCT2016040627248N1 (Continued)
Outcomes Primary outcome:
• determine the miscarriage rate (loss of an intrauterine pregnancy at = 20 weeks’ gestation) in patients
with threatened miscarriage. Timepoint: weekly follow-up until vaginal bleeding has stopped and follow-up
at 20 weeks of pregnancy
Secondary outcome:
• the average duration of vaginal bleeding
Starting date July 2016
Contact information Dr Fatemeh Moradi School of Traditional medicine, Tehran University of Medical Sciences, SarParast St.
, Taleghani St., ValiAsr Blvd. 1449614353 Tehran Iran, Islamic Republic Of Tel:00982166976527 e-mail:
dfmoradi@gmail.com
Notes
NCT015018902011
Trial name or title The impact of progesterone treatment on obstetrical outcome among women with first trimester vaginal
bleeding
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: triple (participant, care provider, investigator)
Primary purpose: prevention
Participants Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable
singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
Interventions Intervention group: progesterone
Control group: placebo
Outcomes Primary outcome measures:
• adverse pregnancy outcomes
• miscarriage (also gestational age of miscarriage)
• sonographic intrauterine hematoma
• IUGR
• placenta previa
• pregnancy-induced hypertension and pre-eclampsia/eclampsia,
• gestational age at delivery, preterm delivery (before 37 weeks); Early preterm delivery (before 34 weeks)
; and very early (before 28 weeks)
• mode of delivery
• placental abruption
• PPROM
• induction of labour
• PPH
• Apgar score
• umbilical cord blood PH at birth
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NCT015018902011 (Continued)
• birthweight
• fetal malformations
• perinatal mortality
• admission to the neonatal unit
Secondary outcome measures:
• uterine artery blood flow velocimetry, systolic to diastolic ratio, pulsatility index, resistance index and
peak systolic velocity
• placental pathological examination; placental weight and presence of infarcts, calcifications, fibrin
deposits or signs of inflammation
Starting date January 2012
Contact information Ralika Hershkovitch, MD
Soroka University Medical Center
Beer Sheva, Israel
Notes
NCT02128685
Trial name or title A randomised double-blind controlled trial of the use of dydrogesterone inwomenwith threatenedmiscarriage
in the first trimester: study protocol for a randomised controlled trial
Methods Double-blind, RCT
Participants A total of 400 women presenting with first-trimester threatened miscarriage will be enrolled
Interventions Intervention group: Dydrogesterone 40 mg orally, followed by 10 mg orally 3 times/d
Control group: placebo
Outcomes • Primary outcome: percentage of miscarriage before 20 weeks of gestation
Starting date Registered on 29 April 2014
Contact information Department of Obstetrics and Gynaecology, QueenMary Hospital, 102 Pokfulam Road, Hong Kong Special
Administrative Region, China. dcmanka@gmail.com
Notes
NCT02145767
Trial name or title Progesterone for the prevention of miscarriage and preterm delivery in women with first trimester bleeding:
PREEMPT trial
Methods Allocation: randomised
Intervention model: parallel assignment
Masking: quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose: prevention
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NCT02145767 (Continued)
Participants Ages eligible for study: 18 years-45 years
Accepts healthy volunteers: yes
Live intrauterine singleton pregnancy of < 14 weeks by crown-rump length on U/S with documented fetal
cardiac activity presence of progestational (subchorionic) hematoma on U/S
Interventions Intervention group: progesterone 200 mg suppository administered vaginally at bedtime until 34 completed
weeks of pregnancy
Control group: placebo similar appearing suppository containing vehicle alone administered vaginally at
bedtime until 34 completed weeks of pregnancy
Outcomes Primary outcomes
• miscarriage
• preterm delivery (< 37 weeks)
Secondary outcomes:
• maternal outcomes
◦ antenatal admissions
◦ treatment of preterm delivery, etc
• Neonatal outcomes:
◦ malformations
◦ growth restriction
◦ prematurity
◦ associated morbidity, etc
• Healthcare outcomes:
◦ hospital costs
Starting date December 2014
Contact information Contact: Andrea Spence
514-418-0875
preempttrial@gmail.com
Notes
NCT02633878
Trial name or title Chinese herbal medicine and micronized progesterone for threatened miscarriage
Methods RCT intervention model: parallel assignment
Masking: quadruple (participant, care provider, investigator, outcomes assessor)
Participants 1656 women age:18-37 years.
Inclusion criteria: pregnant (as confirmed by positive urinary pregnancy tests), vaginal bleeding with or
without abdominal pain, while the cervix is closed by visual exam and the fetus is viable inside the uterine
cavity during early pregnancy (5-10 weeks’ gestation), No previous treatment for miscarriage, ability and
willingness to give informed consent and willingness to be randomised and to take daily study medications
for up to several months
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NCT02633878 (Continued)
Interventions Chinese herbal medicine versus progesterone
Chinese herbal medicine versus progesterone placebo
Chinese herbal medicine placebo versus progesterone
Chinese herbal medicine placebo + progesterone placebo
Outcomes Primary outcome:
• live birth rate
Secondary outcome measures:
• ongoing pregnancy rate (beyond gestation 12 weeks, ongoing pregnancy rate (beyond gestation 20
weeks), ongoing pregnancy rate (beyond gestation 32 weeks),
• live births, premature live births
• anti-ovarian antibody, angiosperm antibody, anticardiolipin antibody, anti-uterus endometrial
antibody, antinuclear antibody
• resistive index of uterus
• pulsatility index of ovary; pulsatility Index of uterus
• biochemical pregnancy loss rate, pregnancy loss rate
• serum progesterone level
• pregnancy-induced hypertension
• diabetes
• APH
• preterm delivery, postdate delivery rate
• pre-eclampsia
• IUGR rate
• small-for-gestational-age infant
• stillbirth rate, neonatal death
• congenital anomaly, birth defect rate
• Zung Self-Rating Anxiety Scale, Zung Self-Rating Depression Scale
Starting date Dec 2015
Contact information No contacts or locations provided
Notes
NCT02690129
Trial name or title Vaginal progesterone for treatment of threatened miscarriage; randomised clinical trial
Methods RCT intervention model: parallel assignment
Masking: single (participant)
Participants 290 women age: 20 years-35 years
Inclusion criteria: pregnant < 24 weeks pregnant presented with bleeding with or without pain, with single
viable fetus (confirmed by U/S examination) and accepting to participate in the trial.
Exclusion criteria: currently under medication for any chronic diseases, hypersensitivity to progesterone,
congenital fetal anomaly, on hormonal treatment in the current pregnancy and women conceived via assisted
reproduction technique
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NCT02690129 (Continued)
Interventions Intervention group: (progesterone group): complete bed rest for first 48-72 hours. Single daily dose of
natural micronised progesterone (Prontogest ® 200 mg) at bedtime for 15 days. If needed, a pain killer as
Indomethacin 50 mg/rectally twice daily up to control of uterine pain. Complete abstaining from sexual
activity or strenuous effort. Rh-ve women will be given a shot of anti-D immunoglobulin 300 uG/IM if they
continue to bleed; after 12 weeks’ gestation or if undergo surgical evacuation
Control group: (placebo): will follow the same plan of management without progesterone support
Outcomes Primary outcome:
• miscarriage rate up to 28 weeks of gestation
Secondary outcome:
• gestational age at delivery or termination of pregnancy
Starting date Feb 2016
Contact information Omar M Shaaban, MD Address: Faculty of Medicine Assiut, Egypt Tel:+201223971457 Email:omshaa-
ban2000@yahoo.com
Notes
NCT02950935
Trial name or title Prospective, double-blind, randomised, placebo controlled, phase iii clinical study assessing the efficacy of
natural progesterone 25mg/bid administered subcutaneously in themaintenance of early pregnancy inwomen
with symptoms of threatened miscarriage
Methods RCT: parallel assignment
Masking: quadruple (participant, care provider, investigator, outcomes assessor)
Participants 268 women age: 18-37 years, BMI: 18-28 kg/m2
Inclusion criteria: pregnant women attending the study sites with the following characteristics: accept to
sign the informed consent form and adhere to the study visit schedule; symptoms of threatened miscarriage
including vaginal bleeding and pelvic pain); U/S proof of viable singleton intrauterine pregnancy (positive
fetal heart beat); gestation week≥ 6 weeks (5 week + 1 day) and < 12 weeks (11 week + 1 day) according to U/
S dating (CRL); closed uterine cervix; subchorionic hematoma, if detected, with < 50% placental detachment
Interventions Intervention group: subcutaneous injection of progesterone solution will be performed twice a day from
onset of threatened miscarriage symptoms until week 12 of pregnancy
Control group: placebo; subcutaneous injection of placebo solution will be performed twice a day from onset
of threatened miscarriage symptoms until week 12 of pregnancy
Outcomes Primary outcome:
• ongoing pregnancy rate at 12 weeks of gestation
Secondary outcome:
• reduction of the frequency of uterine contractions
• pain reduction (using a numerical rating scale)
• reduction of subchorionic hematoma (size of subchorionic hematoma will be measured (in mm) at
screening and after treatment)
• number of women with onset of new threatened miscarriage
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NCT02950935 (Continued)
Starting date April 2017
Contact information Barbara PS Cometti, PHD. Tel:41583601000. Email:barbara.cometti@ibsa.ch
Notes
APH: antepartum haemorrhage; IUGR: intrauterine growth restriction; PPH: postpartum haemorrhage; PPROM: preterm pre-labour
rupture of membranes; U/S: ultrasound
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D A T A A N D A N A L Y S E S
Comparison 1. Progestogens versus placebo or no treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Miscarriage 7 696 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.47, 0.87]
1.1 Oral progestogen versus
no treatment
3 408 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.38, 0.85]
1.2 Vaginal progesterone
versus placebo
4 288 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.47, 1.21]
2 Preterm birth 5 588 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.52, 1.44]
3 Pregnancy-induced hypertension 2 337 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.54, 1.88]
4 Antepartum haemorrhage 2 337 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.30, 1.94]
5 Stillbirth 2 262 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [0.18, 20.49]
6 Congential abnormalities 2 337 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.10, 4.82]
Analysis 1.1. Comparison 1 Progestogens versus placebo or no treatment, Outcome 1 Miscarriage.
Review: Progestogen for treating threatened miscarriage
Comparison: 1 Progestogens versus placebo or no treatment
Outcome: 1 Miscarriage
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Oral progestogen versus no treatment
El-Zibdeh 2009 15/86 15/60 21.0 % 0.70 [ 0.37, 1.32 ]
Pandian 2009 12/96 27/95 32.2 % 0.44 [ 0.24, 0.82 ]
Turgal 2017 6/36 8/35 9.6 % 0.73 [ 0.28, 1.89 ]
Subtotal (95% CI) 218 190 62.8 % 0.57 [ 0.38, 0.85 ]
Total events: 33 (Progestogen), 50 (Control)
Heterogeneity: Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.75 (P = 0.0059)
2 Vaginal progesterone versus placebo
Alimohamadi 2013 13/72 12/73 14.1 % 1.10 [ 0.54, 2.24 ]
Gerhard 1987 0/16 1/17 1.7 % 0.35 [ 0.02, 8.08 ]
Palagiano 2004 4/25 8/25 9.5 % 0.50 [ 0.17, 1.45 ]
0.05 0.2 1 5 20
Progestogen Control
(Continued . . . )
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(. . . Continued)
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yassaee 2014 6/30 10/30 11.9 % 0.60 [ 0.25, 1.44 ]
Subtotal (95% CI) 143 145 37.2 % 0.75 [ 0.47, 1.21 ]
Total events: 23 (Progestogen), 31 (Control)
Heterogeneity: Chi2 = 2.13, df = 3 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Total (95% CI) 361 335 100.0 % 0.64 [ 0.47, 0.87 ]
Total events: 56 (Progestogen), 81 (Control)
Heterogeneity: Chi2 = 4.13, df = 6 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.88 (P = 0.0040)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
0.05 0.2 1 5 20
Progestogen Control
Analysis 1.2. Comparison 1 Progestogens versus placebo or no treatment, Outcome 2 Preterm birth.
Review: Progestogen for treating threatened miscarriage
Comparison: 1 Progestogens versus placebo or no treatment
Outcome: 2 Preterm birth
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alimohamadi 2013 12/72 14/73 50.1 % 0.87 [ 0.43, 1.75 ]
El-Zibdeh 2009 6/86 5/60 21.2 % 0.84 [ 0.27, 2.62 ]
Gerhard 1987 0/17 2/18 8.8 % 0.21 [ 0.01, 4.10 ]
Pandian 2009 6/96 4/95 14.5 % 1.48 [ 0.43, 5.09 ]
Turgal 2017 0/36 1/35 5.5 % 0.32 [ 0.01, 7.70 ]
Total (95% CI) 307 281 100.0 % 0.86 [ 0.52, 1.44 ]
Total events: 24 (Progestogen), 26 (Control)
Heterogeneity: Chi2 = 1.98, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Progestogen Control
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Analysis 1.3. Comparison 1 Progestogens versus placebo or no treatment, Outcome 3 Pregnancy-induced
hypertension.
Review: Progestogen for treating threatened miscarriage
Comparison: 1 Progestogens versus placebo or no treatment
Outcome: 3 Pregnancy-induced hypertension
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Zibdeh 2009 7/86 3/60 20.1 % 1.63 [ 0.44, 6.04 ]
Pandian 2009 12/96 14/95 79.9 % 0.85 [ 0.41, 1.74 ]
Total (95% CI) 182 155 100.0 % 1.00 [ 0.54, 1.88 ]
Total events: 19 (Progestogen), 17 (Control)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Progestogen Control
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Analysis 1.4. Comparison 1 Progestogens versus placebo or no treatment, Outcome 4 Antepartum
haemorrhage.
Review: Progestogen for treating threatened miscarriage
Comparison: 1 Progestogens versus placebo or no treatment
Outcome: 4 Antepartum haemorrhage
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Zibdeh 2009 4/86 3/60 36.9 % 0.93 [ 0.22, 4.01 ]
Pandian 2009 4/96 6/95 63.1 % 0.66 [ 0.19, 2.26 ]
Total (95% CI) 182 155 100.0 % 0.76 [ 0.30, 1.94 ]
Total events: 8 (Progestogen), 9 (Control)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Progestogen Control
Analysis 1.5. Comparison 1 Progestogens versus placebo or no treatment, Outcome 5 Stillbirth.
Review: Progestogen for treating threatened miscarriage
Comparison: 1 Progestogens versus placebo or no treatment
Outcome: 5 Stillbirth
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pandian 2009 0/96 0/95 Not estimable
Turgal 2017 2/36 1/35 100.0 % 1.94 [ 0.18, 20.49 ]
Total (95% CI) 132 130 100.0 % 1.94 [ 0.18, 20.49 ]
Total events: 2 (Progestogen), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Progestogen Control
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Analysis 1.6. Comparison 1 Progestogens versus placebo or no treatment, Outcome 6 Congential
abnormalities.
Review: Progestogen for treating threatened miscarriage
Comparison: 1 Progestogens versus placebo or no treatment
Outcome: 6 Congential abnormalities
Study or subgroup Progestogen Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
El-Zibdeh 2009 2/86 2/60 100.0 % 0.70 [ 0.10, 4.82 ]
Pandian 2009 0/96 0/95 Not estimable
Total (95% CI) 182 155 100.0 % 0.70 [ 0.10, 4.82 ]
Total events: 2 (Progestogen), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Progestogen Control
A P P E N D I C E S
Appendix 1. Search terms for ICTRP and ClinicalTrials.gov
progest* AND miscarriage
progest* AND abortion
dydrogesterone AND miscarriage
dydrogesterone AND abortion
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WH A T ’ S N E W
Date Event Description
27 September 2018 Amended Corrected typo in result in Abstract for the outcome ’preterm birth’
H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 3, 2007
Date Event Description
8 August 2018 Amended Corrected affiliation for Dr Amel Fayed.
8 August 2017 New citation required but conclusions have not
changed
With the addition of the data from the new included
trials, analysis suggested that progestogens are still
probably effective in the treatment of threatened mis-
carriage but may have little or no effect in the rate of
preterm birth. The evidence on congenital abnormal-
ities is uncertain, because the quality of the evidence
for this outcome was based on only two small trials
with very few events and was found to be of very low
quality
8 August 2017 New search has been performed Search updated, 29 new trial reports identified, from
which three trials were included in this update of
the review (Alimohamadi 2013; Turgal 2017; Yassaee
2014), one is awaiting classification (Yadav 2015),10
(in addition to three duplicate), are ongoing and 10 (in
addition to two duplicate) were excluded.We updated
the risk of bias for all included trials. We have assessed
the quality of evidence and included a ’Summary of
findings’ table in this update
30 September 2011 New citation required and conclusions have changed With the addition of the data from the new included
studies, meta-analysis suggested that oral progestogen
is effective in treating threatened miscarriage. Data
analysis also suggested that treatment of women with
threatened miscarriage by progestogens did not in-
crease the risk of congenital abnormalities, pregnancy
induced hypertension nor antepartum haemorrhage.
However these results should be approached with cau-
tion due to the small sample size and the poor method-
ological quality of the included studies
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(Continued)
30 September 2011 New search has been performed Search updated. We have identified two new studies
(El-Zibdeh 2009; Pandian 2009) and included both.
Two new authors (Amel A Fayed and Samia A Es-
maeil) helped prepare this update. We have updated
the methods to reflect the latest Cochrane Handbook
(Higgins 2011a).
14 February 2011 New citation required but conclusions have not
changed
New author helped prepare the latest update.
1 December 2009 New search has been performed Search updated. Three new reports identified and ex-
cluded (Czajkowski 2007; Song 2007; Vincze 2006)
. One trial previously awaiting classification has been
excluded (Zhang 2000).
20 September 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
For the 2017 update, Dr Hayfaa Wahabi participated in the selection of eligible trials, assessment of the trials for inclusion, data
extraction and analysis and grading of evidence. She participated in writing both the initial and final version of the review.
Dr Amel Fayed participated in the selection of eligible trials, assessment of the trials for inclusion, data extraction and analysis.
Dr. Khawater Bahkali participated in the selection of eligible trials, assessment of the trials for inclusion, data extraction and analysis
and grading of evidence. She participated in writing the draft of the review.
Dr Samia Ahmed participated in the selection of eligible trials, assessment of the trials for inclusion, and data extraction. She participated
in writing the draft of the review.
D E C L A R A T I O N S O F I N T E R E S T
Hayfaa A Wahabi: none known
Amel A Fayed: none known
Samia A Esmaeil: none known
Khawater Hassan Bahkali: none known
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S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Review Initiative Project, Saudi Arabia.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. The primary outcome ’Miscarriage’, was previously listed as ’Early miscarriage up to 12 weeks’ and ’Miscarriage later than 12
weeks and less than 23 weeks’. We grouped both outcomes together because the protocol stated that a subgroup analysis for early and
late miscarriage would be carried out when data were available
2. The following outcomes are included in this update.
i) For the mother:
a) pregnancy-induced hypertension
b) antepartum haemorrhage
ii) For the child:
a) intrauterine growth restriction
b) low birthweight
c) birthweight
d) respiratory distress syndrome
3. The methods have been updated to reflect the latest Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a).
For this update, we assessed trial quality for seven selected outcomes using the GRADE approach (see Summary of findings for the
main comparison).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Abortion, Spontaneous [epidemiology]; Abortion, Threatened [∗drug therapy]; Administration, Intravaginal; Congenital Abnormalities
[epidemiology]; Premature Birth [drug therapy; epidemiology; prevention & control]; Progestins [adverse effects; ∗therapeutic use];
Randomized Controlled Trials as Topic
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MeSH check words
Female; Humans; Pregnancy
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